A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)
Study Identifier
P19-831
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Recruitment Complete
Study Details
Medical Condition
Study Drug
N/A
Phase
N/A
Sex
Female & Male
Age
18+ years
Protocol Summary
This study will describe the safety and effectiveness of venetoclax in AML patients in routine clinical practice in Israel. The decision to treat with venetoclax is made by the physician prior to any decision regarding participation in this study.
Study Locations
Location
Status
Location
Meir Medical Center /ID# 213352
Kfar Saba, Central District, Israel, 4428164
Status
Not applicable
Location
Assuta Tel Aviv Medical Center /ID# 213371
Tel Aviv, Central District, Israel, 6971028
Status
Not applicable
Location
HaEmek Medical Center /ID# 213370
Afula, Haifa District, Israel, 1834111
Status
Not applicable
Location
Shaare Zedek Medical Center /ID# 228016
Jerusalem, Jerusalem, Israel, 91031
Status
Not applicable
Location
Hadassah /ID# 213356
Jerusalem, Jerusalem, Israel, 91120
Status
Not applicable
Location
ZIV Medical Center /ID# 229211
Safed, Northern District, Israel, 13100
Status
Not applicable
Showing {first} - {last} of {total} Results